Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DVA vs PACS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DVA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

DVA Overall Winner 6-Pillar Tally: DVA 5 – 1 PACS Matrix Metrics: DVA 8 – 2 PACS

As of Nov 20, 2026, DaVita Inc. (DVA) is the stronger overall head-to-head candidate over PACS Group, Inc. (PACS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DVA carries a Unified Composite Score of 48.8/100 (HOLD) at $161.03 (9.5x Forward P/E, 15.2% operating margin), whereas PACS carries 46.8/100 (HOLD) at $43.67 (15.3x Forward P/E, 7.4% operating margin).

  • Technical & Structure Timing Caution: DVA is currently in a Breakdown options structure phase (RSI 35.6); meanwhile PACS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 39.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DVA vs PACS
DVA NYSE Head-to-Head Winner
DaVita Inc.
Services-Misc Health & Allied Services, Nec
$161.03
+3.0% 1D
Market Cap $9.8B
TTM Revenue $14.2B
Forward P/E 9.5x
Beta / 30D Vol 0.15β · 48% Vol
Unified Composite Score
48.8 / 100 HOLD
Tech 54.0 Fund 58.0 Flow 58.0 Mom 66.4
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 35.6 · SMA20: $180.03 · SMA50: $180.98
PACS NYSE
PACS Group, Inc.
Services-Skilled Nursing Care Facilities
$43.67
+1.49% 1D
Market Cap $6.8B
TTM Revenue $5.71B
Forward P/E 15.3x
Beta / 30D Vol 0.78β · 51% Vol
Unified Composite Score
46.8 / 100 HOLD
Tech 35.0 Fund 48.0 Flow 62.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 39.2 · SMA20: $48.01 · SMA50: $45.43

6-Pillar Scorecard Institutional Category Breakdown (DVA 5 – 1 PACS)

Columns: Metric · DVA · PACS
1. Valuation Multiples DVA
Forward P/E 9.5x 15.3x
Trailing P/E 11.8x 26.2x
PEG Ratio 0.40x 1.22x
EV / Revenue 1.6x 1.8x
2. Growth & Scale DVA
Revenue Growth (YoY) +4.6% +11.5%
Earnings Growth (YoY) +66.7% +15.6%
TTM Revenue (USD) $14.2B $5.71B
Market Cap $9.8B $6.8B
3. Profitability & Quality DVA
Gross Margin 32.3% 17.8%
Operating Margin 15.2% 7.4%
Net Profit Margin 6.5% 4.9%
Return on Equity (ROE) 96.8% 26.5%
4. Balance Sheet & Cash Flow DVA
Cash Generation (TTM) $1.29B $8.2M
Cash Flow Margin 9.1% 0.1%
Net Cash / Leverage $12.9B Net Debt $3.29B Net Debt (2.81x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PACS
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 42.0% (7th %ile) 46.1% (11th %ile)
Put/Call OI Skew 0.68x (Call-Skewed) 0.52x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat DVA
OpEx & R&D Intensity 17.1% of Rev ($2.42B) 10.4% of Rev ($593M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DVA (8) vs PACS (2)
Institutional Metric DVA PACS Criterion Row Edge
Market Capitalization
Scale
$9.8B $6.8B Larger Scale DVA
Trailing P/E Ratio
Valuation
11.8x 26.2x Lower Multiple DVA
Forward P/E Ratio
Valuation
9.5x 15.3x Lower Multiple DVA
Revenue Growth (YoY)
Growth
+4.6% +11.5% Higher Growth PACS
Operating Margin (TTM)
Profitability
15.2% 7.4% Higher Margin DVA
Net Profit Margin
Profitability
6.5% 4.9% Higher Margin DVA
Return on Equity (ROE)
Capital Efficiency
96.8% 26.5% Higher ROE DVA
52-Week Range Position
Momentum
41% ($101–$247) 79% ($14–$52) Stronger Trend PACS
Beta / 30D Volatility
Risk Regime
0.15β · 48% Vol 0.78β · 51% Vol Lower Realized Risk DVA
Unified Institutional Score
Composite Signal
48.8 / 100 (HOLD) 46.8 / 100 (HOLD) Higher Composite DVA
Trailing 12M Revenue (USD)
Operating Scale
$14.2B $5.71B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
32.3% 17.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.40x PEG · 1.6x EV/Rev 1.22x PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.29B ($12.9B Net Debt) $8.2M ($3.29B Net Debt (2.81x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PACS +5.41 pp
DVA: -13.47% · PACS: -8.06%
3M Horizon PACS +7.45 pp
DVA: -8.76% · PACS: -1.31%
6M Horizon PACS +34.56 pp
DVA: -18.88% · PACS: +15.68%
1Y Horizon PACS +119.7 pp
DVA: +39.78% · PACS: +159.48%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DVA Revenue PACS Revenue DVA Op. Margin PACS Op. Margin Margin Leader
FY2018 $11.4B N/A 13.4% N/A DVA
FY2019 $11.4B N/A 14.4% N/A DVA
FY2020 $11.6B N/A 14.7% N/A DVA
FY2021 $11.6B N/A 15.5% N/A DVA
FY2022 $11.6B $2.40B 11.5% 9.6% DVA
FY2023 $12.1B $3.11B 13.2% 6.7% DVA
FY2024 $12.8B $4.09B 16.3% 3.0% DVA
FY2025 $13.6B $5.29B 15.0% 5.9% DVA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DVA BREAKDOWN
98d in phase · OBV DISTRIBUTION
Current IV 42.0%
IV Percentile 7th %ile
Put/Call OI Skew 0.68x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact DVA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PACS CONSOLIDATION
83d in phase · OBV NEUTRAL
Current IV 46.1%
IV Percentile 11th %ile
Put/Call OI Skew 0.52x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PACS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $174.22 · IV 35.2%

DVA vs. PACS: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of DVA ($17,422) vs. PACS ($4,900) against risk-defined 5-day vertical and put-wall option structures.

DVA Spot $174.22 · IV 35.2%
DVA Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $170 / $190 Bull Call Spread

Buy 1x $170C · Sell 1x $190C · 31d

Net Entry $700 Debit
T+5d @ +5% Move +$389 (+56%)
Max Risk / Buffer $700 Capped
5d Edge & Liquidity 1.0x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $165 / $155 Bull Put Spread

Sell 1x $165P · Buy 1x $155P · 31d

Net Entry $252 Credit
Max Credit / Yield +$252 (+33.7% RoM)
Max Risk / Buffer -6.7% Cushion ($748 Mgn)
5d Edge & Liquidity 72% PoP · Liq B
Simulate 5-Day Payoff →
PACS Spot $49.00 · IV 47.5%
PACS Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $50 / $55 Bull Call Spread

Buy 1x $50C · Sell 1x $55C · 32d

Net Entry $103 Debit
T+5d @ +5% Move +$65 (+63%)
Max Risk / Buffer $103 Capped
5d Edge & Liquidity 1.1x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Dec 18 $45 / $40 Bull Put Spread

Sell 1x $45P · Buy 1x $40P · 32d

Net Entry $104 Credit
Max Credit / Yield +$104 (+26.3% RoM)
Max Risk / Buffer -10.3% Cushion ($396 Mgn)
5d Edge & Liquidity 73% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DVA Moat Profile High-Margin Pricing Power Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $9.8B market capitalization and 15.2% operating margin.
OpEx & R&D Reinvestment 17.1% of Rev ($2.42B)
90D Engineering Disclosures 0 Published
PACS Moat Profile Scale & Operating Efficiency Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $6.8B market capitalization and 7.4% operating margin.
OpEx & R&D Reinvestment 10.4% of Rev ($593M)
90D Engineering Disclosures 0 Published

Investor FAQ DVA vs PACS Key Questions & Quantitative Answers

As of Nov 20, 2026, DaVita Inc. (DVA) is the stronger overall head-to-head candidate over PACS Group, Inc. (PACS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). DVA carries a Unified Composite Score of 48.8/100 (HOLD) at $161.03 (9.5x Forward P/E, 15.2% operating margin), whereas PACS carries 46.8/100 (HOLD) at $43.67 (15.3x Forward P/E, 7.4% operating margin). Technical & Structure Timing Caution: DVA is currently in a Breakdown options structure phase (RSI 35.6); meanwhile PACS trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 39.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DVA leads the Growth & Scale pillar: DVA posts +4.6% YoY revenue growth and +66.7% YoY earnings growth on $14.2B TTM revenue (32.3% gross margin, 15.2% operating margin), compared with PACS at +11.5% YoY revenue growth and +15.6% YoY earnings growth on $5.71B TTM revenue (17.8% gross margin, 7.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DVA cumulative revenue shifted +19.6% while PACS shifted +120.4%. In operating R&D and SG&A reinvestment, DVA deploys 17.1% of Rev ($2.42B) (0 90-day corporate R&D disclosures) versus 10.4% of Rev ($593M) (0 disclosures) for PACS.

DVA screens cheaper on headline valuation multiples. DVA trades at 9.5x Forward P/E, 11.8x Trailing P/E, 0.40x PEG, and 1.6x EV/Revenue (9.1% FCF margin), whereas PACS trades at 15.3x Forward P/E, 26.2x Trailing P/E, 1.22x PEG, and 1.8x EV/Revenue (0.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DVA (96.8% ROE) versus PACS (26.5% ROE) capital efficiency.

In options market volatility and institutional positioning, DVA carries 42.0% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.68x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.15β · 48% Vol realized risk). By comparison, PACS carries 46.1% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.78β · 51% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.